ZafGen Raises $14 Million

ZafGen Inc., a Cambridge, Mass.-based developer of an obesity therapy based on the vascular targeting of adipose tissue, has raised $14 million in Series B funding, according to a regulatory filing. Third Rock Ventures was joined by return backer Atlas Venture. The company previously raised around $5.2 million from Atlas and GreatPoint Ventures.